
Oncology NEWS International
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
NCI Drug Discovery Program Pays Off
ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Division of Cancer Treatment, said that over the past decade, NCI's drug discovery and development programs have produced seven new drugs currently being used to treat cancer and AIDS. The program cost about $1.4 billion: $200 million for every New Drug Application filed.
ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Divisionof Cancer Treatment, said that over the past decade, NCI's drugdiscovery and development programs have produced seven new drugscurrently being used to treat cancer and AIDS. The program costabout $1.4 billion: $200 million for every New Drug Applicationfiled.
Dr. Chabner made the report to the National Cancer Advisory Board'sAd Hoc Working Group on NCI Intramural Programs. He added thatduring the decade, increases in AIDS research funding has hada significant effect on the intramural research program. "Intramuralscientists have shifted the focus of their research to followthe money," he said.
Articles in this issue
about 31 years ago
First Results of Avicidin Trialsabout 31 years ago
Chemo Patients Often Develop Menstrual Irregularitiesabout 31 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicabout 31 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationabout 31 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseaseabout 31 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialabout 31 years ago
Ultrasound Breast Screens Useful in Selected Womenabout 31 years ago
New Roles Forecast for Endocrine Therapyabout 31 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsabout 31 years ago
Anticancer Drugs From Zeneca in Regulatory Phase of DevelopmentNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
















































